JACINDA WATKINS: Open Payments
NPI 1447817952 · SAINT PETERS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$926 in 23 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $222 · 2025 $926
Food & beverage: $926
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $191 |
| AstraZeneca Pharmaceuticals LP | 4 | $185 |
| Novo Nordisk Inc | 2 | $141 |
| Lilly USA, LLC | 5 | $116 |
| Calliditas Therapeutics US Inc. | 1 | $92 |
| ABBVIE INC. | 2 | $66 |
| Corcept Therapeutics | 1 | $33 |
| Lundbeck LLC | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: Vanrafia, LOKELMA, Ozempic, JARDIANCE, TARPEYO, VRAYLAR, AIRSUPRA, LEQVIO.
Industry payments across MO — which companies pay providers there.
